A blood-based epigenetic test for early detection of nasopharyngeal carcinoma (NPC).

Annual meeting of the American Society of Clinical Oncology; 2013 May 31- Jun 4; Chicago. Illinois, USA
J Clinical Oncology 31, 2013 (Supplement; Abstract 6063)


OBD signs an extension of its Collaboration Agreement with a major Japanese Pharmaceutical Company.

Oxford Biodynamics signs an extension of its Collaboration Agreement with a major Japanese Pharmaceutical Company under which Oxford Biodynamics Pte Limited, a wholly owned subsidiary of Oxford Biodynamics based in Singapore, to conduct an extended non-invasive test for breast cancer using Japanese samples.


Genome Institute of Singapore (GIS) and Oxford Biodynamics Pte (OBD) have signed a major Collaboration Agreement to develop EpiSwitch™ technology for epigenetic stem cell differentiation.

GIS and OBD, a wholly owned subsidiary of Oxford Biodynamics Limited, have signed a Collaboration Agreement to jointly develop the EpiSwitchTM technology to create a focused EpiSwitchTM epigenetic signature to compare IPSCS, ESCS and Progenitor cell lines.